CORE-COMPARE Pilot Study

Ultra-High Resolution Computed Tomography (CT) vs. Conventional CT for Detecting Obstructive Coronary Artery Disease (CAD) The CORE-COMPARE Pilot Study

The utility of Ultra High-Resolution Computed Tomography (UHR-CT) compared to conventional CT in all-comers (i.e., a generally lower-risk population) remains uncertain but is an important area of study in order to justify wider spread implementation and use of this technology, particularly in light of reports of significantly higher radiation exposure with UHR-CT, as well as longer scan times. The availability of technology to reconstruct conventional resolution (CR) simulation images from the raw CT acquisition data acquired on the UHR-CT scanner offers a unique platform to study this question without subjecting individuals to two different scans.

The primary objective of this study is to generate preliminary data in support of the hypothesis that noninvasive UHR-CT is superior to conventional resolution CT for identifying patients with obstructive CHD.

Study Overview

• Status: Recruiting
• Conditions: Coronary Heart Disease (CHD)
• Intervention / Treatment: Device: Aquilion Precision; Device: Conventional Computed Tomography

• Study Type: Interventional
• Enrollment (Estimated): 140
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Joao Lima, Professor; Phone Number: 4106141284; Email: jlima@jhmi.edu

Study Locations

• United States
  • Maryland
    • Baltimore, Maryland, United States, 21205
      • Recruiting
      • Johns Hopkins School of Medicine
      • Contact: Michelle lHughes-Lukoski; Email: mhughe17@jh.edu

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Patients aged 21-85 years
• Clinical history suggestive of CHD who are referred by their primary cardiologist for further evaluation via Computed tomography angiography (CTA) will be asked to participate.
• Women of child bearing potential must demonstrate a negative pregnancy test within 24 hours of the study CTA.
• Ability to understand and willingness to sign the Informed Consent Form.

Exclusion Criteria:

• Known allergy to iodinated contrast media.
• History of multiple myeloma or previous organ transplantation
• Elevated serum creatinine (> 1.5mg/dl) OR calculated creatinine clearance of < 60 ml/min (using the Cockcroft-Gault formula
• Atrial fibrillation or uncontrolled tachyarrhythmia, or advanced atrioventricular block (second or third degree heart block)
• Evidence of severe symptomatic heart failure (NYHA Class III or IV);
• Known or suspected moderate or severe aortic stenosis
• History of prior percutaneous coronary intervention (PCI) in one or more vessel or history of coronary arterial bypass grafting (CABG)
• Suspected acute coronary syndrome
• Presence of any other history or condition that the investigator feels would be problematic

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: UHR-CT (Ultra-High-Resolution Computed Tomography-Aquilion Precision); Participants in this arm undergo CT scans using the Ultra-High-Resolution CT imaging modality.	Device: Aquilion Precision; Ultra-High Resolution CT (UHR CT) capable of resolving anatomy as small as 150 microns, providing CT image quality with resolution typically seen only in cath labs. The UHR detector is newly designed to provide more than twice the resolution when compared with today's CT technology, with an all-new detector as well as tube, gantry and reconstruction technologies.
Active Comparator: CR-CT (Conventional Resolution Computed Tomography); Participants in this arm receive CT scans using the Conventional Resolution CT imaging modality.	Device: Conventional Computed Tomography; Conventional reconstruction Computed Tomography (CT) represents a pivotal approach in medical imaging.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
agreement between the number of patients with >70% stenosis detected by ultra-high-resolution tomography compared to conventional tomography, with catheterization considered as the gold standard.	The ultra-high-resolution CT images (UHRCT) and the reconstructed conventional CT resolution images (CRCT) will be independently reviewed by two observers (with a 60-day washout period between both images). The stenoses will be classified according to the Society of Cardiovascular Computed Tomography (SCCT) classification system (<25%, 25-49%, 50-69%, 70-99%, and occluded). Patients with stenosis greater than 70% will be flagged. The primary outcome will be assessed for patients that underwent a clinically indicated invasive angiography (ICA). To compare agreement between UHRCT and CRCT studies while using ICA as the gold-standard, a concordance meta-analysis will be employed. This involves evaluating the agreement measures from each study, standardizing the results, and then comparing the concordance results of the two studies with the third study, considered the gold standard.	Up to 24 Months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Segment-Based Analysis for Obstructive Stenosis:	Stenosis greater than 70% and 50-69% will be identified and flagged in both imaging modalities (UHRCT and CRCT). The agreement in identifying these specific levels of stenosis will be compared.	Up to 24 Months
Diagnostic Confidence Assessment:	Confidence level will be classified by the 2 observers for both imaging modalities using the following scale: 1. Very Unsure, 2. Unsure, 3. Moderately Confident, 4. Confident, 5. Highly Confident.	Up to 24 Months
Interobserver Variability Analysis:	The agreement in the stenosis classification at patient and vessel level will be assessed using Cohen's kappa statistic.	Up to 24 Months
Assessment of vascular and plaque metrics:	A comparison will be performed between both imaging modalities for the following parameters: vessel volume, lumen volume, wall/lumen ratio, total plaque volume, percentage of calcified component, percentage of non-calcified component.	Up to 24 Months
Pericoronary Adipose Tissue Analysis:	The perivascular fat attenuation index (FAI) will be calculated for all the three major vessels, right coronary artery (RCA), left circumflex artery (LCX) and left anterior descending (LAD) in both datasets and the results will be compared.	Up to 24 Months

Collaborators and Investigators

• Sponsor: Johns Hopkins University
• Collaborators: Canon Medical Systems, USA
• Investigators: Principal Investigator: Joao Lima, Professor, MD

Study record dates

Study Major Dates

• Study Start (Actual): April 5, 2021
• Primary Completion (Estimated): April 5, 2026
• Study Completion (Estimated): April 5, 2027

Study Registration Dates

• First Submitted: March 24, 2021
• First Submitted That Met QC Criteria: December 5, 2023
• First Posted (Actual): December 14, 2023

Study Record Updates

• Last Update Posted (Actual): December 14, 2023
• Last Update Submitted That Met QC Criteria: December 5, 2023
• Last Verified: December 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Arteriosclerosis; Arterial Occlusive Diseases; Heart Diseases; Coronary Artery Disease; Myocardial Ischemia; Coronary Disease
• Other Study ID Numbers: IRB00234130

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Sharing Time Frame: Data requests can be submitted starting 12 months after article publication. Data will be made accessible up to 24 months with extensions considered as needed.
• IPD Sharing Access Criteria: Access provided upon request.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; ANALYTIC_CODE; CSR

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: No